Bio-Rad acquires AbD Serotec
Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products, has announced that it has purchased AbD Serotec, a division of MorphoSys, for approximately €53 million in cash.
AbD Serotec is one of the world’s leading antibody manufacturers, offering over 15,000 antibodies, kits and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as other facilities in Germany and the US.
“We are pleased to have AbD Serotec join Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO.
“With AbD Serotec’s comprehensive catalogue of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA and cell sorting.”
CSL fellowships fund immunity research, AI-designed proteins
Australian scientists Dr Carolien van de Sandt and Dr Rhys Grinter have each been awarded CSL...
Leukaemia Foundation funds ongoing blood cancer research at UWA
The $3m in funding is understood to represent the single largest non-government investment in...
Jian Zhou Medal recognises anaesthesia, blood pressure research
The Australian Academy of Health and Medical Sciences has announced Professor Britta Regli-von...
